Philips also concluded an agreement with insurers to pay Philips EUR 540 million to cover Respironics recall-related product liability claims
Sales reflect continued strong growth in oncology and vaccines
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Pharma Solutions operates 10 research and development and/or production sites globally
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway
Furthering cell therapy ambition across oncology and autoimmune diseases
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Subscribe To Our Newsletter & Stay Updated
